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Background:Despite many recent advances in endovascular therapy (EVT), peripheral artery disease (PAD) is an
increasing health problem with high mortality. Heart-type fatty acid-binding protein (H-FABP) and high-
sensitivity troponin T (hsTnT) are markers of ongoing myocardial damage and have been reported to be useful
indicators of future cardiovascular events. However, it remains to be determined whether H-FABP and hsTnT
can predict adverse clinical outcomes in patients with PAD.
Methods and results:We enrolled 208 de novo PAD patients who underwent EVT. SerumH-FABP and hsTnTwere
measured in all patients before EVT. During the median follow-up period of 694 days, there were 40 major ad-
verse cardiovascular and cerebrovascular events (MACCEs) including all-cause deaths, and re-hospitalizations
due to cardiovascular and cerebrovascular diseases and amputations. H-FABP and hsTnTwere found to be higher
in patients with critical limb ischemia (CLI) compared to those without this condition. Multivariate Cox propor-
tional hazard regression analysis revealed that both H-FABP and hsTnT were independent predictors of MACCEs
after adjustment for confounding factors. Kaplan–Meier analysis demonstrated that patients in the highest tertile
according to H-FABP levels, aswell as those in the highest hsTnT tertile, were at greatest risk forMACCEs. The net
reclassiﬁcation index was signiﬁcantly improved by the addition of H-FABP as well as the addition of hsTnT to
traditional risk factors.
Conclusion: The myocardial damage markers H-FABP and hsTnT were increased in PAD patients with CLI and
could predict MACCEs in PAD patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Peripheral artery disease (PAD) is an athero-occlusive disease of the
lower limb arteries resulting in impairedmortality. The presence of PAD
is an independent predictor of cardiovascular events [1]. Despite medi-
cal advances, patientswith PADhave three times higher risk of all-cause
mortality in general and of cardiovascular mortality in particular com-
pared to those without PAD [2]. Although reduced lower extremity per-
formance was reported to be a prognostic marker for mortality, little is
known about useful biomarkers for identifying PADpatients at high risk.
Cardiac biomarkers have been reported to be useful in predicting an
increased risk of death, not only in patients with heart disease, but also
for subjects in the general population [3–5]. Heart-type fatty acid-
binding protein (H-FABP) is a lowmolecularweight protein in the cyto-
sol of cardiomyocytes, and is rapidly released into the circulation fromPulmonology, and Nephrology,
, Yamagata 990-9585, Japan.
. Watanabe).
. This is an open access article underdamaged myocardial tissue [6]. Therefore, H-FABP is a marker for myo-
cardial damage. Cardiac troponin T, which is a myoﬁbrillar component
of cardiomyocytes, is an established marker for myocardial damage
[7]. Myocardial damage markers can be used to risk stratify patients
with various types of heart disease [8–11]. However, the prognostic
value of these myocardial damage markers has not yet been elucidated
in patients with PAD.
The purpose of the present study was to determine whether
myocardial damage, assessed by measuring the concentrations of
H-FABP and high-sensitivity troponin T (hsTnT) in the bloodstream,
can predict major adverse cardiovascular and cerebrovascular events
(MACCEs) and risk stratify patients with PAD.
2. Methods
2.1. Study population
We carried out a prospective study of 208 de novo patients who
were admitted to our hospital for the treatment of PAD. A diagnosisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Comparison of clinical characteristics between patients with and without MACCEs.
Variables All patients
n = 208
Event free
n = 168
MACCE
n = 40
P value
Age (years old) 74 ± 8 73 ± 8 77 ± 6 0.0022
Men/women 175/33 140/28 35/5 0.5168
Hypertension, n (%) 172 (83%) 140 (84%) 32 (80%) 0.6165
Diabetes mellitus, n (%) 98 (47%) 77 (46%) 21 (53%) 0.5350
Hyperlipidemia, n (%) 134 (64%) 111 (66%) 23 (58%) 0.3088
Previous IHD, n (%) 65 (31%) 42 (25%) 23 (58%) b0.0001
Previous cerebrovascular
disease
38 (18%) 26 (15%) 12 (30%) 0.0326
Fontaine II/III/IV 157/27/24 137/20/11 20/7/13 b0.0001
CLI, n (%) 24 (10%) 11 (7%) 13 (28%) 0.0004
CKD, n (%) 81 (39%) 60 (35%) 21 (53%) 0.0384
Endovascular therapy data
Iliac artery, n (%) 142 (68%) 120 (71%) 22 (55%) 0.0448
Femoropopliteal artery, n (%) 123 (59%) 96 (57%) 27 (68%) 0.2311
Tibial or peroneal artery, n (%) 29 (14%) 18 (11%) 11 (28%) 0.0059
Stent, n (%) 175 (90%) 140 (90%) 35 (88%) 0.5999
Pre ABI 0.58 ± 0.18 0.58 ± 0.18 0.58 ± 0.16 0.9609
Post ABI 0.89 ± 0.19 0.90 ± 0.18 0.84 ± 0.25 0.1811
Blood examination
Log10 BNP (pg/mL) 1.62 ± 0.51 1.52 ± 0.46 1.99 ± 0.51 b0.0001
Loge H-FABP (ng/mL) 1.50 ± 0.57 1.4 ± 0.49 1.87 ± 0.68 b0.0001
Log10 hsTnT (pg/mL) 1.07 ± 0.37 1.00 ± 0.33 1.25 ± 0.46 0.0002
Crea (mg/dL) 0.86 ± 0.27 0.83 ± 0.24 0.97 ± 0.36 0.0031
Medication
Aspirin, n (%) 146 (70%) 117 (70%) 29 (73%) 0.7226
Clopidogrel, n (%) 117 (57%) 96 (57%) 21 (53%) 0.5947
Cilostazol, n (%) 69 (33%) 53 (33%) 16 (40%) 0.3075
Other antiplatelet drug, n (%) 44 (21%) 34 (20%) 10 (25%) 0.5075
ACEIs and/or ARBs, n (%) 132 (63%) 106 (63%) 26 (65%) 0.8221
Calcium channel blockers,
n (%)
118 (57%) 99 (59%) 19 (48%) 0.1898
Statin, n (%) 103 (50%) 85 (57%) 18 (45%) 0.5247
Data are expressed as mean ± SD, number (percentage).
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers;
BNP, brain natriuretic peptide; CKD, chronic kidney disease; CLI, critical limb ischemia;
H-FABP, heart-type fatty acidbinding protein; hsTnT, high-sensitivity troponin T;MACCEs,
major adverse cardiovascular and cerebrovascular events.
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and computed tomographic angiography. Endovascular therapy (EVT)
was performed by experienced cardiologists who followed the Trans-
Atlantic Inter-society Consensus II (TASC II) guideline recommendation.
The physicians were blinded to the results of the biochemical analyses,
and medical therapy was independently administered to optimize im-
provement of symptoms. The exclusion criteria of the present study
were acute coronary syndrome within the 3 months preceding admis-
sion, estimated glomerular ﬁltration rate less than 30 mL/min/1.72 m2,
andmalignant disease. Blood samples were obtained in the earlymorn-
ing 1 or 2 days before the ﬁrst EVT. Demographic and clinical data
including age, gender, ABI, and Fontaine class were collected from
interviews with the patients, as well as from their medical records.
Medications and ABI at discharge were recorded from the hospital
medical records.
2.2. Ethics statement
The Institutional Ethics Committee of the Yamagata University School
of Medicine approved the study, and all participants providedwritten in-
formed consent. The procedures were performed in accordance with the
Helsinki Declaration.
2.3. Measurements
Hypertensionwasdeﬁnedas systolicbloodpressure(BP)≥140mmHg
or diastolic BP ≥90 mm Hg or antihypertensive medication use. Dia-
betes mellitus was deﬁned as glycosylated hemoglobin A1c ≥6.5%
(National Glyco-hemoglobin Standardization Program), or anti-
diabetic medication use. Hyperlipidemia was deﬁned as total choles-
terol ≥220 mg/dL or triglyceride ≥150 mg/dL or anti-hyperlipidemic
drug use. Chronic kidney disease (CKD) was deﬁned as a reduced
glomerular ﬁltration rate (b60 mL/min/1.73 m2) according to the
Kidney Disease Outcomes Quality Initiative clinical guideline [12,13].
2.4. Biochemical markers
Blood samples for measurements of serum H-FABP concentra-
tions were drawn and centrifuged at 2500 g for 15 min at 4 °C within
30 min of collection, and the obtained serum was stored at −70 °C
until analysis. H-FABP levels weremeasured using a two-step sand-
wich enzyme-linked immunosorbent assay (ELISA) kit (MARKIT-M
H-FABP, Dainippon Pharmaceutical Co. Ltd., Tokyo, Japan), as previously
described [14]. Concentrations of high-sensitivity troponin T were
measured by using a fourth-generation electrochemiluminescence im-
munoassay on an Elecsys 2010 automatic analyzer (Elecsystroponin-T,
Roche Diagnostics, Tokyo, Japan) [15]. Blood samples were also
obtained for measuring the concentrations of brain natriuretic
peptide (BNP). These samples were transferred to chilled tubes con-
taining 4.5 mg ethylenediaminetetraacetic acid disodium salt and
aprotinin (500 U/mL), and centrifuged at 1000 g for 15 min at 4 °C.
The clariﬁed plasma samples were frozen, stored at −70 °C, and
thawed just before the assay was performed. BNP concentrations
were measured using a commercially available radioimmunoassay
speciﬁc for human BNP (Shiono RIA BNP Assay Kit, Shionogi Co.
Ltd., Tokyo, Japan) [16,17].
2.5. Endpoint and follow-up
All subjects were prospectively followed for a median period
of 694 days (interquartile range, 349–1070 days). Patients were
followed up by telephone or medical records twice a year for
1500 days. The endpoint was MACCEs including all-cause death
and rehospitalization due to cardiovascular and cerebrovascular dis-
eases such as stroke, ischemic heart disease, heart failure, abdominalaortic aneurysm, and the development of critical limb ischemia (CLI)
and amputation.
2.6. Statistical analysis
Normality of continuous variables was checked by a Shapiro–
Wilk test. Since the concentrations of H-FABP, hsTnT, and BNP were
not normally distributed, we used loge [H-FABP], log10 [hsTnT], and
log10 [BNP] for all analyses. All values are expressed as the mean ±
standard deviation. Continuous and categorical variables were com-
pared with t-tests and chi-square tests, respectively. A Cox propor-
tional hazard analysis was performed to determine independent
predictors for MACCEs and signiﬁcant predictors selected in the uni-
variate analysis were entered into a multivariate analysis. Survival
curves were constructed with the Kaplan–Meier method and com-
pared using log-rank tests. The receiver operating characteristics
(ROC) curves for MACCEs were constructed and used as a measure
of the predictive accuracy of H-FABP and hsTnT on MACCEs. The
area under the ROC curve was calculated by using the trapezoidal
rule [18]. In addition, we calculated the net reclassiﬁcation index
(NRI) and the integrated discrimination index (IDI) to measure the
quality of improvement for the correct reclassiﬁcation according to
the addition of H-FABP or hsTnT to the model. A value of P b 0.05
was considered statistically signiﬁcant. All statistical analyses were
performed with a standard program package (JMP version 8; SAS
37Y. Otaki et al. / BBA Clinical 4 (2015) 35–41Institute Inc., Cary, NC, USA and R 3.0.2 with additional packages in-
cluding Rcmdr, Epi, pROC, and PredictABEL).
3. Results
3.1. Comparison of clinical characteristics between patients with and
without MACCEs
The baseline characteristics of the patients are shown in Table 1.
There were 175 men and 33 women. The mean loge [H-FABP] and
log10 [hsTnT] were 1.50 ng/mL and 1.07 pg/mL, respectively. Patients
with MACCEs during the course of the study were older and had higher
prevalence rates of CLI, previous ischemic heart disease (IHD), previous
cerebrovascular disease, and CKD than those without MACCEs. The pa-
tients with MACCEs also had higher levels of BNP, H-FABP, hsTnT, and
creatinine compared to thosewithout it. Therewas no signiﬁcant differ-
ence in EVT data excluding occlusion of tibial or peroneal artery and
medications at discharge between patients with and without MACCEs.
3.2. Myocardial damage marker levels in CLI, IHD, and CKD settings
As shown in Fig. 1, patients with CLI as well as those with CKD had
higher levels of H-FABP compared to those without either of these con-
ditions. There was, however, no signiﬁcant difference in H-FABP levels
between patients with and without previous IHD. hsTnT levels were
also higher in patients with CLI as well as those with CKD compared to
those without either of these conditions, but in contrast to the case of
H-FABP, hsTnT levels were also higher in patients with previous IHD
than in those without IHD (Fig. 2).
3.3. Myocardial damage and MACCEs in patients with PAD
During the follow-up period, there were 40MACCEs including 9 all-
cause deaths, 25 re-hospitalizations due to cardiovascular and cerebro-
vascular events, and 6 re-hospitalizations due to the development of CLI
and amputation.0
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Fig. 1.H-FABP levels in patients with and without CLI, CKD and previous IHD. (A) H-FABP levels
patients with CKD than thosewithout CKD. (C) Therewas no signiﬁcant difference inH-FABP lev
CLI, critical limb ischemia; CKD, chronic kidney disease and IHD, ischemic heart disease.To determine the risk factors for MACCEs, we performed univariate
and multivariate Cox proportional hazard regression analyses. In the
univariate analysis, H-FABP and hsTnT were signiﬁcantly associated
withMACCEs (Table 2). Age, previous cerebrovascular disease, previous
IHD, CLI, CKD, and BNP were also related to MACCEs. Signiﬁcant predic-
tors in univariate analysis were entered into multivariate Cox propor-
tional hazard regression analysis in a stepwise manner. Both H-FABP
and hsTnT were found to be independent predictors of MACCEs in pa-
tients with PAD after adjustment of previous IHD and BNP (H-FABP,
hazard ratio, 2.61; 95% conﬁdence interval, 1.81–3.76; P b 0.0001 and
hsTnT, hazard ratio, 1.77; 95% conﬁdence interval, 1.12–2.69; P =
0.0083; Fig. 3A). Since myocardial damage markers were affected by
CLI, CKD, and previous IHD, we entered these risk factors into the mul-
tivariate Cox proportional hazard regression analysis. Both H-FABP
and hsTnT were found to be independent predictors of MACCEs after
adjusting for CLI, previous IHD, and CKD (H-FABP, hazard ratio, 2.75;
95% conﬁdence interval, 1.94–3.87; P b 0.0001 and hsTnT, hazard
ratio, 2.14; 95% conﬁdence interval, 1.42–3.23; P = 0.0003; Fig. 3B).
3.4. Risk stratiﬁcation
All subjectswere divided into tertiles according to theirH-FABP levels:
ﬁrst tertile (b1.28 ng/mL, n = 69), second tertile (1.28–1.65 ng/mL, n =
69), and third tertile (N1.65 ng/mL, n = 70). A Kaplan–Meier analysis
demonstrated that the ratio of MACCEs was highest in the 3rd tertile
of H-FABP than in the other two groups (Fig. 4A). All subjects were also
divided into tertiles according to their hsTnT levels: ﬁrst tertile
(b0.90 pg/mL, n = 69), second tertile (0.90–1.23 ng/mL, n = 69), and
third tertile (N1.23 ng/mL, n = 70). As was found for H-FABP, the
Kaplan–Meier analysis of the hsTnT tertiles also demonstrated that the
ratio of MACCEs was highest in the 3rd tertile (Fig. 4B).
3.5. Comparison of the prognostic values of H-FABP and hsTnT
To compare the prognostic capacity of H-FABPwith that of hsTnT, an
ROC analysis was performed. AUC of H-FABP, sensitivity, and speciﬁcity0
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Fig. 2. hsTnT levels in patients with and without CLI, CKD and previous IHD. (A) hsTnT levels were higher in patients with CLI than those without CLI. (B) hsTnT levels were higher in pa-
tients with CKD than those without CKD. (C) hsTnT levels were higher in patients with IHD than those without IHD. hsTnT, high-sensitivity troponin T; CLI, critical limb ischemia; CKD,
chronic kidney disease and IHD, ischemic heart disease.
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loge [H-FABP] was 1.46 ng/mL. AUC of hsTnT, sensitivity, and speciﬁcity
were 0.681, 65%, and71%, respectively. The cut-off value of log10 [hsTnT]
was 1.2 pg/mL. AUC of H-FABP was thus signiﬁcantly greater than that
of hsTnT (P = 0.0223).
3.6. Improving reclassiﬁcation by addition of H-FABP or hsTnT to predict
MACCEs
To determine whether model ﬁt and discrimination improve with
addition of H-FABP or of hsTnT to the basic predictors such as age,
previous IHD, CKD, and CLI, we evaluated the improvement of NRI and
IDI. As shown in Table 3, both NRI and IDI were signiﬁcantly improvedTable 2
Univariate andmultivariate Cox proportional hazard analysis of predictingMACCEs in pa-
tients with peripheral artery disease.
Variables Hazard
ratio
95% conﬁdence
interval
P value
Univariate analysis
Age (years old) 1.07 1.02–1.12 0.0034
Men/women 1.01 0.39–2.59 0.9815
Hypertension 1.44 0.66–3.14 0.3568
Diabetes mellitus 1.22 0.65–2.27 0.5368
Hyperlipidemia) 1.36 0.72–2.58 0.3461
Previous IHD 3.57 1.92–6.66 b0.0001
Previous cerebrovascular disease 2.44 1.23–4.83 0.0108
CLI 4.08 2.03–8.19 b0.0001
CKD 1.97 1.06–3.68 0.0324
Stent, n (%) 2.87 0.67–12.17 0.1522
Pre ABI 0.98 0.13–7.69 0.9836
Post ABI 0.24 0.04–1.50 0.1278
Log10 BNP 2.44 1.75–3.42 b0.0001
Loge H-FABP 2.48 1.86–3.28 b0.0001
Log10 hsTnT 2.54 1.78–3.65 b0.0001
Abbreviation as in Table 1.by the addition of H-FABP. NRI was also signiﬁcantly improved by the
addition of hsTnT to the basic predictors, but the addition of hsTnT did
not yield any signiﬁcant difference in IDI.
4. Discussion
The results of this study revealed ﬁve novel ﬁndings: 1) patients
with MACCEs had higher levels of H-FABP and hsTnT compared to
those without MACCE; 2) patients with CLI had higher levels of H-
FABP and hsTnT than thosewithout CLI; 3)multivariate Cox proportion-
al hazard regression analysis revealed that both H-FABP and hsTnT
levels independently predicted the occurrence of MACCEs; 4) the
Kaplan–Meier analysis demonstrated that the prevalence of MACCEs
was greatest in patients in the highest H-FABP tertile and in the highest
hsTnT tertile; and 5) a model including H-FABP as well as one including
hsTnT showed signiﬁcantly improved abilities to predict MACCEs in pa-
tients with PAD.
4.1. Myocardial damage in PAD
Previously, troponin leakage detected by a highly sensitive assay kit
(hsTnT N0.003 ng/mL) was reported to occur in 20–25% of the general
population and 60% of elderly adults [19–21]. In the present study,
troponin leakage was observed in 85% of PAD patients. On the other
hand, H-FABP was detected in all PAD patients examined, with a
mean loge [H-FABP] of 1.50 ng/mL. We previously reported a mean
loge [H-FABP] level of 1.25 ng/mL in the general population [5]. These
ﬁndings suggest that the patients with PAD in our study had a greater
level of myocardial damage than that of the general population. H-
FABP was reported to be more sensitive than TnT for detection of latent
myocardial damage in patients with CHF [17]. Since, in contrast to tro-
ponin, H-FABP is a low molecular weight protein, cytosolic H-FABP is
easily released into the circulation through the porous membranes of
damaged myocardial cells in the absence of cardiomyocyte necrosis
2.75
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Fig. 3.Multivariate Cox proportional hazard regression analysis for predicting MACCEs in patients with PAD. (A) Hazard ratio after adjustment for IHD and BNP. (B) Hazard ratio after ad-
justment for CLI, CKD, and IHD. BNP, brain natriuretic peptide; CLI, critical limb ischemia; CKD, chronic kidney disease; IHD, ischemic heart disease andMACCEs, major adverse cardiovas-
cular and cerebrovascular events.
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have detected latent myocardial damage in all patients with PAD in
the present study.
In accordance with previous reports [19,24], the presence of CKD
and IHD was associated with myocardial damage in patients with
PAD. Troponin levels were reported to be elevated in PAD patients
with CLI [25,26]. In the present study, we showed that patients with
CLI had higher levels of H-FABP and hsTnT compared to those without
CLI. Although the precise mechanism is unclear, these ﬁndings suggest
an association of CLI with myocardial damage.
4.2. Clinical outcomes related to myocardial damage in patients with PAD
Previous studies have not fully determined whether biochemical
markers could be useful for identiﬁcation and risk stratiﬁcation of
these high-risk PAD patients, although BNPwas reported to be useful
for the diagnosis of PAD in patients with diabetes mellitus and to0 250 500 750 1000 1250 1500
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Fig. 4. (A) Kaplan–Meier analysis of MACCEs among patients in all H-FABP tertiles. (B) Kaplan–M
binding protein; hsTnT, high-sensitivity troponin T and MACCEs, major adverse cardiovascularpredict MACCEs in patients with PAD [27,28]. Our results showed,
for the ﬁrst time, that H-FABP and hsTnT, diagnostic markers of
myocardial infarction [22], are the feasible markers for MACCEs in
patients with PAD.
Linnemann et al. reported that troponin leakage, detected with a
conventional cardiac TnT assay kit (N0.01 ng/mL), occurred in 21.3% of
PAD patients that were studied, and was signiﬁcantly associated with
MACCEs [26]. We also showed that troponin leakage, detected by
high-sensitivity cardiac TnT, can predict MACCEs in patients with PAD.
The abnormal cut-off value of 1.2 pg/mL (0.016 ng/mL) for log10
[hsTnT] in the present study indicates that it is possible that troponin
leakage detected by both high-sensitivity cardiac TnT and conventional
TnT could identify PAD patients at high risk.
We also showed the clinical usefulness of H-FABP in patients with
PAD. The abnormal cut-off value of 1.46 ng/mL (4.3 ng/mL) for loge
[H-FABP] in the present study is equal to that shown to predict cardiac
events in patients with CHF and implantable cardioverter deﬁbrillatorsB)
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Table 3
Statistics for model ﬁt and improvement with the addition of H-FABP or hsTnT on the prediction of MACCE.
AUC (P value) NRI (95% CI, P value) IDI (95% CI, P value)
Age+CLI+IHD+CKD 0.811 Reference Reference
+H-FABP 0.837
(P = 0.1834)
0.5032
(0.1651–0.8413, P = 0.0035)
0.0549
(0.0047–0.1051, P = 0.0321)
+hsTnT 0.812
(P = 0.9184)
0.3929
(0.0545–0.7312, P = 0.0228)
0.0152
(−0.0074–0.0378, P = 0.1882)
AUC, area under the curve; 95% CI, 95% conﬁdence interval; NRI, net reclassiﬁcation index; IDI, integrated discrimination index; CLI, critical limb ischemia; CKD, chronic kidney disease;
IHD, ischemic heart disease; H-FABP, heart-type fatty acid binding protein and hsTnT, high-sensitivity troponin T.
40 Y. Otaki et al. / BBA Clinical 4 (2015) 35–41[8,16]. Latent myocardial damage detected by H-FABP, in particular at
concentrations greater than 4.3 ng/mL, could provide additional clinical
information about MACCEs in patients with PAD.
Myocardial damage is associatedwith the development of heart fail-
ure, ischemic heart disease, and cerebrovascular disease [22,29–31]. In
addition, myocardial damage is associated with CLI, which is a risk for
mortality and amputation in patients with PAD [32]. Therefore, the
myocardial damage markers H-FABP and hsTnT could be useful for
predicting MACCEs including amputations in patients with PAD.
4.3. Limitations
First, this study collected baseline information at a single time point.
Subsequent medical interventions may have affected serum H-FABP
and hsTnT levels. Second, since H-FABP levels in patients with CKD
are elevated due to impaired elimination of H-FABP, we could not
completely remove the effect of kidney dysfunction on H-FABP levels.
Third, although acute coronary syndrome was excluded in the present
study, hsTnT levelswere higher in patients with IHD than in thosewith-
out IHD.We could not completely eliminate the impact of IHD on hsTnT
levels. Finally, the study population was relatively small in the present
investigation. A further study with a larger population is needed to
determine precisely what constitutes abnormal levels of H-FABP and
hsTnT in patients with PAD.
5. Conclusions
Latent myocardial damage detected by H-FABP and hsTnT is in-
creased in PAD patients with CLI. Notably, both H-FABP and hsTnT
could predict MACCEs in patients with PAD, suggesting that they are
promising markers for early identiﬁcation of PAD patients at high risk.
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